Key MessagePertuzumab, trastuzumab, and two commonly used anthracycline-based regimens for the neoadjuvant treatment of early breast cancer were associated with cardiac/general safety profiles and pathologic complete response rates consistent with prior pertuzumab studies. These data support the use of pertuzumab and trastuzumab with a taxane following doxorubicin- or epirubicin-based chemotherapy in the neoadjuvant setting.

Introduction
============

HER2 is overexpressed/gene-amplified in ∼15%--20% of breast cancers (BC) \[[@mdx773-B1]\] and associated with poor prognoses. Trastuzumab plus chemotherapy has progression-free survival (PFS)/overall survival benefits in HER2-positive metastatic BC \[[@mdx773-B2]\]. Pertuzumab, trastuzumab, and docetaxel showed further benefits, with significantly improved PFS/overall survival versus placebo, trastuzumab, and docetaxel \[[@mdx773-B3], [@mdx773-B4]\]. Pertuzumab, trastuzumab, and docetaxel is efficacious in the neoadjuvant setting, with a 17.8% increase in pathologic complete response (pCR, ypT0/is ypN0) rates versus trastuzumab plus docetaxel in NeoSphere \[[@mdx773-B5]\], and similar benefits in additional studies \[[@mdx773-B6], [@mdx773-B7]\]. Exploratory PFS and disease-free survival results from NeoSphere and TRYPHAENA supported pCR benefits \[[@mdx773-B8], [@mdx773-B9]\].

Trastuzumab is associated with a risk of cardiac toxicity, particularly when given with anthracyclines. In BCIRG006 (trastuzumab plus chemotherapy in early BC \[EBC\]), incidences of congestive heart failure were 2.0% and 0.4% in the anthracycline- and nonanthracycline arms, respectively \[[@mdx773-B10]\]. Higher cardiac event rates with trastuzumab were also seen in studies of anthracycline-containing regimens ± trastuzumab \[[@mdx773-B11], [@mdx773-B12]\]. Therefore, cardiac safety within the context of chemotherapy regimen is an important consideration.

In CLEOPATRA, there was no increased cardiac risk (heart failure) with pertuzumab \[[@mdx773-B3], [@mdx773-B4]\]; no additional/long-term cardiotoxicities were associated with combination therapy in NeoSphere \[[@mdx773-B8]\]. Pertuzumab plus trastuzumab was associated with little additional toxicity in NeoSphere \[[@mdx773-B5]\] and TRYPHAENA \[[@mdx773-B6]\] (mainly increased incidence, but not severity, of diarrhea, rash, and mucositis); there was little impact on doses received, dose interruptions/modifications/discontinuations, or treatment-related mortality \[[@mdx773-B5], [@mdx773-B6]\]. NCCN guidelines recommend pertuzumab-containing regimens for HER2-positive BC. While pertuzumab plus trastuzumab has an acceptable safety profile in combination with epirubicin, when BERENICE was designed there were no doxorubicin data, and limited data on pertuzumab, trastuzumab, and paclitaxel in EBC (GeparSepto assessed paclitaxel/nab-paclitaxel, pertuzumab, and trastuzumab followed by epirubicin and cyclophosphamide \[[@mdx773-B7]\]).

The ongoing BERENICE study (NCT02132949) was designed to evaluate the cardiac safety of two neoadjuvant anthracycline-/taxane-based regimens with pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive BC, and normal cardiac function. We present the primary analysis: cardiac safety during the neoadjuvant period (clinical cutoff at the date of last patient's breast surgery).

Patients and methods
====================

BERENICE is a nonrandomized, phase II, open-label, multicenter, multinational cardiac safety study across 75 centers/12 countries in full accordance with Good Clinical Practice guidelines/Declaration of Helsinki.

All participants provided written informed consent. The protocol and modifications were approved by independent ethics committees.

Procedures
----------

Eligible patients were investigator-assigned to cohorts (Figure [1](#mdx773-F1){ref-type="fig"}). In the neoadjuvant period, cohort A patients received four q2w cycles of dose-dense doxorubicin plus cyclophosphamide (ddAC) followed 2 weeks later by 12 qw paclitaxel injections, while cohort B patients received four q3w cycles of fluorouracil, epirubicin, and cyclophosphamide then four q3w cycles of docetaxel. In both cohorts, four q3w cycles of trastuzumab and pertuzumab were started with taxane therapy and continued in the adjuvant setting (up to 13 cycles to complete 1 year of treatment). Surgery was scheduled after eight cycles of preoperative therapy. All study drugs were given intravenously. See [supplementary data](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online, for dose modification, and [supplementary Figure S1](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online, for management of HER2-targeted treatment based on left ventricular ejection fraction (LVEF) decreases. Optional granulocyte-colony stimulating factor support could be given per local practice. Patients could withdraw consent at any time or be withdrawn by the investigator/sponsor for safety reasons, if in the patient's best interests, or for noncompliance with the protocol.

![Study design. BC, breast cancer; ddAC, dose-dense doxorubicin plus cyclophosphamide; ECOG, Eastern Cooperative Oncology Group; FEC, fluorouracil, epirubicin, and cyclophosphamide; HR, hormone receptor; LVEF, left ventricular ejection fraction; q2w, every 2 weeks; q3w, every 3 weeks; qw, every week. Only one cohort was opened at a time at any given site, and was defined before any patients were enrolled at that site. Investigator choice of cohort was based on local/regional practice.](mdx773f1){#mdx773-F1}

Assessments
-----------

The primary end point was cardiac safety of neoadjuvant treatment assessed by incidence of New York Heart Association (NYHA) class III and IV heart failure and LVEF declines (≥10 percentage-points from baseline and to a value of \<50% \[symptomatic and asymptomatic\]) by echocardiography or multiple-gated acquisition scan. LVEF assessments were conducted at screening/baseline and within 3 days before day 1 of cycles 5 and 7 during the neoadjuvant period. Adverse events (AEs) were assessed throughout the treatment period per National Cancer Institute--Common Terminology Criteria for Adverse Events (NCI-CTCAE) V4.0. Safety data are regularly reviewed by the Steering Committee (sponsor representatives, investigators, plus an independent cardiology expert). Tumors were assessed clinically at screening/baseline and at each cycle during neoadjuvant treatment. Patients are also assessed for recurrence at cycles 9, 13, 17, and 21 during adjuvant treatment, and at study completion/termination visits, per local practice. Secondary end points included general safety during the neoadjuvant period (including incidence and severity of AEs/serious AEs; laboratory test anomalies) and all efficacy end points. The main efficacy end point was pCR in the breast and lymph nodes (ypT0/is ypN0; total pCR). pCR assessments were reviewed by an external pathology expert. Exploratory efficacy end points included local pathologist-assessed pCR rate and rate by major intrinsic BC subtype. To classify patients by intrinsic BC subtype, gene expression analyses were carried out by applying the Nanostring nCounter platform. Within the set of genes analyzed, the panel of genes required to assess the intrinsic BC subtypes as published by Parker et al was included \[[@mdx773-B13]\]. The PAM50 subtype prediction to describe the major intrinsic subtypes (HER2-enriched, luminal A, luminal B, and basal-like) was carried out using the random-forest-based classifier described by Wilson et al \[[@mdx773-B14]\]. Further end point details are presented in the [supplementary data](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online.

Safety was assessed in all patients who received ≥1 dose of study medication; pCR, in the intention-to-treat population.

Statistical methods
-------------------

No formal sample size calculation/statistical hypothesis testing was performed. Results were summarized descriptively. Exact Clopper-Pearson 95% CIs of expected rates (NYHA class III/IV heart failure rate \<3% and LVEF decline rate of ≤6%) \[[@mdx773-B5], [@mdx773-B6]\] were used to evaluate cardiac safety.

Results
=======

Population
----------

Patients were enrolled July 2014 to August 2015: 199 were assigned to cohort A; 202, to cohort B ([supplementary Figure S2](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online). Intention-to-treat populations were 199 and 201 patients, respectively; safety populations, 199 and 198. Clinical cutoff was March 3, 2016, median (interquartile range) follow-up was 14.5 (13.9--15.5) months in cohort A and 15.1 (14.5--15.8) months in cohort B.

Demographics/baseline characteristics were similar in each cohort (Table [1](#mdx773-T1){ref-type="table"}). Treatment exposure during the neoadjuvant period is shown in [supplementary Table S1](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online. Table 1.Baseline demographics and tumor characteristics for the intention-to-treat populationCharacteristicCohort A:Cohort B:ddAC → TPHFEC → DPH*n* = 199*n* = 201Median age, years (IQR)49.0 (42.0--59.0)49.0 (42.0--59.0)Age group \<4039 (19.6%)38 (18.9%) 40--65140 (70.4%)142 (70.6%) \>6520 (10.1%)21 (10.4%)Female patients199 (100%)200 (99.5%)Estrogen and/or progesterone receptor status (centrally assessed) Positive128 (64.3%)124 (61.7%) Negative65 (32.7%)75 (37.3%) Unknown6 (3.0%)2 (1.0%)Primary tumor TX01 (0.5%)[^a^](#tblfn2){ref-type="table-fn"} T01 (0.5%)[^a^](#tblfn2){ref-type="table-fn"}0 T118 (9.0%)12 (6.0%) T2138 (69.3%)130 (64.7%) T333 (16.6%)45 (22.4%) T49 (4.5%)13 (6.5%)Regional lymph nodes NX8 (4.0%)9 (4.5%) N080 (40.2%)74 (36.8%) N192 (46.2%)98 (48.8%) N216 (8.0%)15 (7.5%) N33 (1.5%)5 (2.5%)Histologic subtype Ductal171 (85.9%)176 (87.6%) Lobular9 (4.5%)4 (2.0%) Mucinous1 (0.5%)0 Comedo4 (2.0%)0 Tubular2 (1.0%)0 Not otherwise specified14 (7.0%)19 (9.5%) Other8 (4.0%)8 (4.0%)Histologic grade*n* = 198*n* = 201 GX[^b^](#tblfn3){ref-type="table-fn"}3 (1.5%)9 (4.5%) G14 (2.0%)2 (1.0%) G267 (33.8%)56 (27.9%) G3108 (54.5%)106 (52.7%) Unknown[^c^](#tblfn4){ref-type="table-fn"}16 (8.1%)28 (13.9%)Intrinsic subtype[^d^](#tblfn5){ref-type="table-fn"}*n* = 199*n* = 201 Luminal A33 (16.6%)31 (15.4%) Luminal B24 (12.1%)15 (7.5%) Basal-like11 (5.5%)5 (2.5%) HER2-enriched80 (40.2%)95 (47.3%) Not applicable^e^19 (9.5%)26 (12.9%) Missing[^f^](#tblfn7){ref-type="table-fn"}32 (16.1%)29 (14.4%)[^2][^3][^4][^5][^6][^7][^8][^9]

Incidence of NYHA class III and IV heart failure
------------------------------------------------

Three patients (1.5%) in cohort A experienced four NYHA class III/IV heart failure events (Table [2](#mdx773-T2){ref-type="table"}). One patient experienced two events (one class III and one class IV); due to the close chronology, Steering Committee members considered that these could represent continuation of one event. All occurred during neoadjuvant HER2 antibody treatment and all patients discontinued treatment. Recoveries were recorded for 2/4 events (the patient with two events recovered from the class IV event only). No patient in cohort B experienced any events. Table 2.Cardiac safety during the neoadjuvant period in the safety populationCohort A:Cohort B:ddAC → TPHFEC → DPH*n* = 199*n* = 198NYHA class III/IV heart failure during HER2 antibody treatment in the neoadjuvant period[^a^](#tblfn10){ref-type="table-fn"} Patients with at least one NYHA class III/IV heart failure3 (1.5%; 95% CI 0.31% to 4.34%)0 (95% CI 0% to 1.85%) Number of events40 NCI-CTCAE grade, patients  Grade 31 (0.5%)0  Grade 42 (1.0%)0 NYHA classification, events  Class III3 (1.5%)0  Class IV1 (0.5%)0LVEF declines during the neoadjuvant period[^a^](#tblfn10){ref-type="table-fn"}^,b^ Patients with at least one LVEF decline13 (6.5%; 95% CI 3.5% to 10.9%)4 (2.0%; 95% CI 0.6% to 5.1%)  Number of LVEF declines, events195  Onset before neoadjuvant HER2-targeted therapy (cycles 1--4), patients01 (0.5%)  Onset during neoadjuvant HER2-targeted therapy (cycles 5--8), patients13 (6.5%)3 (1.5%) Patients with at least one confirmed LVEF decline[^c^](#tblfn12){ref-type="table-fn"}2 (1.0%; 95% CI 0.1% to 3.6%)1 (0.5%; 95% CI 0% to 2.8%)[^10][^11][^12][^13][^14]

Incidence of LVEF declines
--------------------------

Thirteen patients (6.5%) in cohort A and four (2.0%) in cohort B experienced ≥1 LVEF decline (Table [2](#mdx773-T2){ref-type="table"}). Patients with a decline should have had treatment withheld and a repeat evaluation ∼3 weeks later. Confirmed declines (≥2 consecutive declines during the neoadjuvant period) were observed in two (1.0%) patients in cohort A and one (0.5%) in cohort B; all during neoadjuvant HER2-targeted therapy. Declines in the neoadjuvant period were generally reversible in most patients at the time of analysis, often with recovery by next assessment.

General safety
--------------

The most common AEs (any-grade) during the neoadjuvant period were nausea, diarrhea, and alopecia (Table [3](#mdx773-T3){ref-type="table"}). The most common grade 3--4 AEs were blood and lymphatic system disorders, with febrile neutropenia the most common event, followed by neutropenia (Table [3](#mdx773-T3){ref-type="table"}). This was in keeping with the higher proportion of patients who received optional prophylactic bone marrow support in cohort A. Neutropenia recorded as "neutrophil count decreased" was reported in 9 patients (4.5%) in cohort A and 12 (6.1%) in cohort B. No grade 5 AEs were reported. The most common serious AEs were febrile neutropenia and diarrhea. Ten patients (5.1%) in cohort B experienced grade 3--4 stomatitis (no cases were reported in cohort A). The most common reason for pertuzumab/trastuzumab discontinuation was ejection fraction decline (including one patient who discontinued but did not have a confirmed decline). Table 3.General safety during the neoadjuvant period in the safety populationPatients with at least one:Cohort A: ddAC → TPHCohort B: FEC → DPH*n* = 199*n* = 198AE (any grade)197 (99.0%)198 (100%)Grade 3--4 AE99 (49.7%)108 (54.5%)Serious AE45 (22.6%)52 (26.3%)AE leading to pertuzumab or trastuzumab discontinuation10 (5.0%)4 (2.0%)Most common grade 3--4 AEs (≥2% of patients) Febrile neutropenia14 (7.0%)34 (17.2%) Neutropenia24 (12.1%)17 (8.6%) Diarrhea6 (3.0%)20 (10.1%) Neutrophil count decreased9 (4.5%)12 (6.1%) Fatigue2 (1.0%)9 (4.5%) Anemia6 (3.0%)5 (2.5%) Stomatitis010 (5.1%) White blood cell count decreased8 (4.0%)4 (2.0%) Vomiting2 (1.0%)8 (4.0%) Mucosal inflammation2 (1.0%)7 (3.5%) Nausea5 (2.5%)4 (2.0%) Hypokalemia4 (2.0%)3 (1.5%) Neutropenic sepsis06 (3.0%) Alanine aminotransferase increased4 (2.0%)2 (1.0%) Bone marrow failure1 (0.5%)4 (2.0%) Device-related infection4 (2.0%)1 (0.5%) Neuropathy peripheral4 (2.0%)0[^15]

Efficacy
--------

pCR rates were 61.8% (95% CI 54.7% to 68.6%) and 60.7% (95% CI 53.6% to 67.5%) in cohorts A and B, respectively, and higher in hormone receptor (HR)-negative versus HR-positive disease (Figure [2](#mdx773-F2){ref-type="fig"}A).

![pCR (ypT0/is ypN0) (A) in the intention-to-treat (ITT) population and (B) by intrinsic breast cancer subtype.^a^ D, docetaxel; ddAC, dose-dense doxorubicin plus cyclophosphamide; FEC, fluorouracil, epirubicin, and cyclophosphamide; H, trastuzumab; HR, hormone receptor; P, pertuzumab; pCR, pathologic complete response; T, paclitaxel. Six patients in cohort A and two in cohort B had missing central HR assessments. ^a^Patients were classified by intrinsic BC subtype using gene expression analyses carried out by applying the Nanostring nCounter platform and the PAM50 subtype prediction used to describe the major intrinsic subtypes (see [supplementary data](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online). ^b^The statistical model applied did not allow categorization into any of the subgroups. ^c^Technical failure (assay failure or failure to extract RNA).](mdx773f2){#mdx773-F2}

Local pathologist-assessed rates were 63.8% (95% CI 56.7% to 70.5%) in cohort A and 61.2% (95% CI 54.1% to 68.0%) in cohort B, including five patients in cohort A and four in cohort B with nodal stage NX. Of these, five patients did not have nodes assessed at surgery but were considered by the local pathologist to have achieved pCR.

Most patients had HER2-enriched BC (Table [1](#mdx773-T1){ref-type="table"}), and the highest pCR rate was observed in this group (75.0% in cohort A and 73.7% in cohort B; Figure [2](#mdx773-F2){ref-type="fig"}B). The pCR rate was similar in luminal A and B groups across both cohorts (Figure [2](#mdx773-F2){ref-type="fig"}B).

Discussion
==========

The primary objective of BERENICE was to evaluate cardiac safety of trastuzumab, pertuzumab, and eight cycles of neoadjuvant chemotherapy (four anthracycline-based followed by four of dual HER2-targeted therapy plus taxane).

Overall incidence of NYHA class III/IV heart failure during neoadjuvant treatment was low and consistent with TRYPHAENA \[[@mdx773-B6]\]. Notably, BERENICE included a longer neoadjuvant period (eight versus six chemotherapy cycles) \[[@mdx773-B6]\].

General safety was consistent with anticipated toxicity profiles of these regimens. Incidence of diarrhea associated with the taxane period was lower in cohort A; however, other reports have shown no difference in rates across taxanes when given with pertuzumab and trastuzumab \[[@mdx773-B15]\]. Diarrhea was mostly low-grade, and only one patient (cohort B), discontinued pertuzumab/trastuzumab as a result. pCR rates were high in both cohorts and consistent with previous reports \[[@mdx773-B5], [@mdx773-B6]\]. Previous studies have reported pCR rates of 22%--64% for combinations of HER2-targeted therapy plus chemotherapy \[[@mdx773-B5], [@mdx773-B16]\]. The high rate in HR-negative disease was consistent with data on trastuzumab plus pertuzumab ± taxanes \[[@mdx773-B29]\]. Lower rates in HR-positive disease were consistent with the lower rates observed in luminal A and B subtypes. The high pCR rate in the HER2-enriched subtype was consistent with data demonstrating that this subtype could identify patients who would most likely benefit from dual HER2-blockade \[[@mdx773-B30]\]. Our distributions of relevant intrinsic subtypes (HER2-enriched and luminal A) are also broadly reflective of those reported in a HER2-positive population \[[@mdx773-B31]\]. Patients will be followed for long-term efficacy outcomes.

BERENICE has limitations due to its design. As it is nonrandomized, the chemotherapy backbone's contribution to the data cannot be assessed. No control arm also means that the impact of pertuzumab alone on the safety/efficacy of the regimen cannot be assessed.

The safety/efficacy of pertuzumab plus trastuzumab and chemotherapy versus placebo plus trastuzumab and chemotherapy in the adjuvant setting was recently reported in the APHINITY trial, where pertuzumab significantly improved invasive disease-free survival with no new safety signals being identified \[[@mdx773-B32]\]. BERENICE, KRISTINE \[[@mdx773-B16]\], and PEONY (NCT02586025) will evaluate pertuzumab plus trastuzumab treatment continuing from the neoadjuvant into the adjuvant setting. These trials will assess 1 year of dual HER2-targeted antibody therapy in EBC, spanning the neoadjuvant and/or adjuvant periods.

Conclusion
----------

Treatment with pertuzumab, trastuzumab, and common anthracycline-containing chemotherapy regimens for the neoadjuvant treatment of EBC resulted in cardiac and general safety profiles, and pCR rates, consistent with prior pertuzumab studies. This is the first study to investigate ddAC followed by paclitaxel with pertuzumab and trastuzumab in the neoadjuvant setting. The safety profiles and high pCR rates in both cohorts support the use of pertuzumab and trastuzumab with a taxane following doxorubicin- or epirubicin-based chemotherapy in the neoadjuvant setting.
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[^1]: Members of the BERENICE Study Group are listed in the [supplementary data](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online.

[^2]: Data are *n* (%) unless stated otherwise.

[^3]: Patient was misdiagnosed.

[^4]: Unevaluable.

[^5]: Not evaluated.

[^6]: Patients were classified by intrinsic BC subtype using gene expression analyses carried out by applying the Nanostring nCounter platform and the PAM50 subtype prediction used to describe the major intrinsic subtypes (see [supplementary data](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online).

[^7]: The statistical model applied did not allow categorization into any of the subgroups.

[^8]: Technical failure (assay failure or failure to extract RNA).

[^9]: D, docetaxel; ddAC, dose-dense doxorubicin plus cyclophosphamide; FEC, fluorouracil, epirubicin, and cyclophosphamide; H, trastuzumab; IQR, interquartile range; P, pertuzumab; T, paclitaxel.

[^10]: 95% CIs were calculated with the use of the Clopper-Pearson method.

[^11]: Includes events with onset from the first dose of pertuzumab or trastuzumab before surgery through the day before the first dose of any study drug after surgery. If a patient withdrew without entering the adjuvant period, the table includes all AEs with onset from first dose of pertuzumab or trastuzumab through 42 days after last dose of any study drug or on the day of target surgery, whichever is later. Multiple occurrences of the same events in one individual are counted only once in the patient frequency counts.

[^12]: Measured by ECHO/MUGA.

[^13]: Confirmed LVEF declines are defined as at least two consecutive readings of declines in LVEF, and single declines are defined as only one reading of declines (no consecutive readings) in LVEF.

[^14]: CI, confidence interval; D, docetaxel; ddAC, dose-dense doxorubicin plus cyclophosphamide; FEC, fluorouracil, epirubicin, and cyclophosphamide; H, trastuzumab; LVEF, left ventricular ejection fraction; NCI-CTCAE, National Cancer Institute---Common Terminology Criteria for Adverse Events; NYHA, New York Heart Association, P, pertuzumab; T, paclitaxel.

[^15]: AE, adverse event; D, docetaxel; ddAC, dose-dense doxorubicin plus cyclophosphamide; FEC, fluorouracil, epirubicin, and cyclophosphamide; H, trastuzumab; P, pertuzumab; T, paclitaxel.
